Business
Arcutis Announces Promotions on Executive Management Team
Strategic appointments support further growth and position Company for future success WESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Arcutis
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Strategic appointments support further growth and position Company for future success WESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced several promotions to support further growth of Arcutis and the ZORYVE® (roflumilast) portfolio. Patrick Burnett, MD, PhD, FAAD, chief medical officer, has been promoted to executive vice president, chief medical officer. Dr. Burnett joined Arcutis in August 2020 and has led the advancement of the Arcutis pipeline and scientific evidence generation. His accomplishments include the completion of numerous Phase 3 programs for ZORYVE, multiple regulatory approvals of ZORYVE in the United States and Canada, as well as preclinical development efforts for ARQ-255 and ARQ-234. Prior to Arcutis, Dr. Burnett, who is a dermatologist, served as chief medical officer at Verrica Pharmaceuticals and as associate vice president of clinical development at Sun Pharmaceuticals where he oversaw the company’s dermatology and rheumatology pipeline. L. Todd Edwards, chief commercial officer, has been promoted to executive vice president, chief commercial officer. Mr. Edwards is an industry veteran with more than 25 years of experience in sales, marketing, market access, and general management experience. Since joining Arcutis in September 2023, Mr. Edwards has revamped Arcutis’ commercial operations and has driven dramatic growth of the ZORYVE franchise. Previously, Mr. Edwards served as group vice president and business unit head of immunology at Incyte where he led the successful launch and commercialization of their topical JAK inhibitor for atopic dermatitis, as well as senior vice president and head of global immunology operations and strategy at UCB. Kent Taylor has been promoted to senior vice president of sales, having joined Arcutis in late November of 2023 as vice president of sales. This promotion comes in recognition of Mr. Taylor’s strong sales performance and exceptional leadership on the launch of ZORYVE foam and ZORYVE cream. An industry veteran with over 25 years of experience in dermatology, Mr. Taylor has held sales and marketing leadership roles at multiple companies prior to joining Arcutis, including Incyte, Encor...